Comparative Pharmacology
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus PRAVASTATIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus PRAVASTATIN SODIUM.
ATORVASTATIN CALCIUM vs PRAVASTATIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Lowers LDL cholesterol, triglycerides, and increases HDL cholesterol by upregulating hepatic LDL receptor expression.
10-80 mg orally once daily, starting at 10-20 mg; maximum dose 80 mg/day.
10-40 mg orally once daily; initiate at 10-20 mg and titrate based on response.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 11–24 h); the active metabolite half-life is 20–30 h; clinical context: supports once-daily dosing despite shorter HMG-CoA reductase inhibitory half-life due to prolonged pharmacodynamic effect.
Terminal elimination half-life is 1.3-2.6 hours; despite short half-life, HMG-CoA reductase inhibition persists longer due to effective hepatic extraction and enterohepatic recirculation.
Primarily biliary excretion (approx. 70%) as metabolites; renal excretion accounts for <2% of the administered dose; fecal elimination of metabolites and parent drug (approx. 90%).
Primarily biliary (60% as unchanged drug and metabolites), with approximately 20% renal excretion; fecal elimination accounts for about 70% of total clearance.
Category C
Category D/X
Statin
Statin